Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

(2013) Rochelle P. Walensky et al.   ANNALS OF INTERNAL MEDICINE

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

(2013) Maryline Bonnet et al.   LANCET INFECTIOUS DISEASES

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

(2013) Lars-Magnus Andersson et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

(2013) Calvin J Cohen et al.   BMJ Open

Managed Problem Solving for Antiretroviral Therapy Adherence

(2013) Robert Gross et al.   JAMA Internal Medicine

A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study

(2012) Torsak Bunupuradah et al.   ANTIVIRAL THERAPY

Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients

(2012) A Buscher et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

(2011) Calvin Cohen et al.   AIDS

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

(2011) Pedro Cahn et al.   AIDS

Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders

(2011) Cristian Pop-Eleches et al.   AIDS

Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review

(2011) Sara Garfield et al.   BMC Medical Research Methodology

Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction

(2011) Renato Maserati et al.   CURRENT HIV RESEARCH

Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine

(2011) Miwako Honda et al.   INTERNAL MEDICINE

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA

(2011) N. Clumeck et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies

(2011) Till Bärnighausen et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

(2011) Jean-Michel Molina et al.   LANCET INFECTIOUS DISEASES

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

(2011) Jean Nachega et al.   Patient Preference and Adherence

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

(2010) David R Bangsberg et al.   AIDS

Short Communication: Comparable Safety and Efficacy with Once-Daily Versus Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of the Randomized Trial M05-730

(2010) Juan González-García et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

(2010) Victor Musiime et al.   ANTIVIRAL THERAPY

Comparison of Once‐Daily versus Twice‐Daily Combination Antiretroviral Therapy in Treatment‐Naive Patients: Results of AIDS Clinical Trials Group (ACTG) A5073, a 48‐Week Randomized Controlled Trial

(2010) Charles Flexner et al.   CLINICAL INFECTIOUS DISEASES

Sequential meta-analysis: an efficient decision-making tool

(2010) Ingeborg van der Tweel et al.   Clinical Trials

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

(2010) Eugenia Vispo et al.   HIV CLINICAL TRIALS

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

(2010) R E Campo et al.   INTERNATIONAL JOURNAL OF STD & AIDS

The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study

(2010) Vanessa Cooper et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

(2010) M. Nelson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

Sequential methods for random-effects meta-analysis

(2010) Julian P. T. Higgins et al.   STATISTICS IN MEDICINE

Estimating required information size by quantifying diversity in random-effects model meta-analyses

(2009) Jørn Wetterslev et al.   BMC Medical Research Methodology

Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis

(2009) Jean‐Jacques Parienti et al.   CLINICAL INFECTIOUS DISEASES

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

(2009) Daniel Podzamczer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks

(2009) Joseph Gathe et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

(2009) Esteban Martínez et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients

(2008) David Wright et al.   HIV CLINICAL TRIALS

Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression

(2008) Brian A. Boyle et al.   HIV CLINICAL TRIALS

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

(2008) D Maitland et al.   HIV MEDICINE

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

(2008) Jesper Brok et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Mobile phones: exceptional tools for HIV/AIDS, health, and crisis management

(2008) Richard Lester et al.   LANCET INFECTIOUS DISEASES

Adherence with lopinavir/ritonavir (LPV/r) tablet and SoftGel (SGC) capsule based antiretroviral regimens and predictors of early treatment compliance

(2008) TJ Podsadecki et al.   Journal of the International AIDS Society

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

(2007) Jørn Wetterslev et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY